Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term open-label extension of treprostinil palmitil inhalation powder in pulmonary hypertension associated with interstitial lung disease
2022-001950-45Phase 2Active
- Sponsor
- Insmed Incorporated
- Start
- Nov 2022
- Modality
- Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Inhalation Devices → Device-based Delivery → Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of treprostinil palmitil in pulmonary hypertension associated with interstitial lung disease (PH-ILD), sponsored by Insmed Incorporated. Primary endpoint: Frequency and severity of treatment-emergent adverse events. Started Nov 2022; status: active.
02
Drugs
treprostinil palmitil
03
Conditions
pulmonary hypertension associated with interstitial lung disease (PH-ILD)
Beyond the preview
Go deeper on 2022-001950-45.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-001950-45.